Artiva Biotherapeutics (ARTV) EBT (2023 - 2026)
Artiva Biotherapeutics (ARTV) posted quarterly EBT of -$35.2 million for Q1 2026, up 4.46% year-over-year from -$33.7 million in Q1 2025, and down 66.17% quarter-over-quarter from -$21.2 million in Q4 2025.
Artiva Biotherapeutics (ARTV) EBT (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has reported EBT for 4 consecutive years, with -$35.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT rose 4.46% year-over-year to -$35.2 million; the TTM figure through Mar 2026 stood at -$116.5 million (up 4.44% YoY), while the FY2025 annual figure was -$87.7 million, down 34.2% from the prior year.
- EBT retreated to -$35.2 million in Q1 2026 per ARTV's latest filing, from -$21.2 million in the prior quarter.
- Across five years, EBT topped out at $11.2 million in Q3 2023 and bottomed at -$36.8 million in Q1 2025.
- Historically, EBT has averaged -$22.0 million across 4 years, with a median of -$23.3 million in 2024.
- Annual changes were most pronounced in 2024 — EBT tumbled 400.97% — and 2025, when it soared 30.87%.
- Artiva Biotherapeutics' EBT stood at -$11.6 million in 2023, then tumbled by 100.05% to -$23.2 million in 2024, then gained by 8.73% to -$21.2 million in 2025, then tumbled by 66.17% to -$35.2 million in 2026.
- Business Quant data shows ARTV's EBT at -$35.2 million in Q1 2026, -$21.2 million in Q4 2025, and -$23.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Artiva Biotherapeutics | 451.28 Mn | 451.28 Mn | - | -36.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.09 Mn |
| Mar 31, 2026 | -35.20 Mn |
| Dec 31, 2025 | -21.18 Mn |
| Sep 30, 2025 | -23.36 Mn |
| Jun 30, 2025 | -36.75 Mn |
| Mar 31, 2025 | -36.84 Mn |
| Dec 31, 2024 | -23.21 Mn |
| Sep 30, 2024 | -33.80 Mn |
| Jun 30, 2024 | -28.05 Mn |
| Mar 31, 2024 | -13.84 Mn |
| Dec 31, 2023 | -11.60 Mn |
| Sep 30, 2023 | 11.23 Mn |
| Jun 30, 2023 | -11.32 Mn |